EUVIMEDEUVIMED entdecken
Crossref

Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B

Gilles Gosselin

HAMDAN MEDICAL JOURNAL · 2014

DOI: 10.7707/hmj.401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HAMDAN MEDICAL JOURNAL, 2014. Verfasst von Gilles Gosselin.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A unique series of simple synthetic L -enantiomer nucleosides had been shown by our former laboratories to inhibit hepatitis B virus (HBV) replication. Among them, β -L-2 ′ -deoxythymidine (LdT) or telbivudine (Sebivo®, Novartis Pharmaceuticals, Basel, Switzerland) had the most potent, selective and specific activity against HBV replication, and was selected as an attractive clinical development candidate for the treatment of chronic HBV infection, a worldwide and significant cause of liver-related morbidity and mortality.

Zitieren

APA

Gosselin, G. (2014). Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B. HAMDAN MEDICAL JOURNAL. https://doi.org/10.7707/hmj.401

Vancouver

Gosselin G. Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B. HAMDAN MEDICAL JOURNAL. 2014. doi:10.7707/hmj.401

BibTeX
@article{Gosselin2014,
  author = {Gosselin, Gilles},
  title = {Telbivudine – from the discovery of its antiviral activity to a marketed drug (Tyzeka®, Sebivo®) for the treatment of chronic hepatitis B},
  journal = {HAMDAN MEDICAL JOURNAL},
  year = {2014},
  doi = {10.7707/hmj.401}
}
Kostenlos starten →